Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

Achilles Therapeutics, a biotech company which develops new immunotherapies that target the improved treatment of tumours without harming healthy tissue, has successfully raised $175.5 million through its initial public offering.

Achilles is a spinout formed in 2016 by Cancer Research UK’s Commercial Partnerships team alongside Syncona, with the support of UCL Business, the commercialisation arm of UCL and a part of UCL Innovation & Enterprise, and The Francis Crick Institute.

Read the full article on UCL’s website: https://www.ucl.ac.uk/news/2021/apr/ucl-spin-out-achilles-therapeutics-raises-1755m-develop-new-immunotherapies